Analysts Set Guardian Pharmacy Services, Inc. (NYSE:GRDN) Target Price at $42.83

Guardian Pharmacy Services, Inc. (NYSE:GRDNGet Free Report) has been given an average rating of “Moderate Buy” by the nine ratings firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $43.8333.

Several brokerages recently issued reports on GRDN. Zacks Research lowered shares of Guardian Pharmacy Services from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Oppenheimer upped their target price on Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an “outperform” rating in a report on Friday. Bank of America increased their target price on Guardian Pharmacy Services from $42.00 to $47.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. Wall Street Zen upgraded Guardian Pharmacy Services from a “hold” rating to a “buy” rating in a report on Sunday. Finally, Truist Financial boosted their price target on Guardian Pharmacy Services from $43.00 to $47.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th.

Read Our Latest Stock Analysis on GRDN

Hedge Funds Weigh In On Guardian Pharmacy Services

A number of large investors have recently made changes to their positions in GRDN. Valiant Capital Management L.P. raised its position in shares of Guardian Pharmacy Services by 15.8% in the 4th quarter. Valiant Capital Management L.P. now owns 1,232,463 shares of the company’s stock valued at $37,085,000 after purchasing an additional 167,741 shares during the last quarter. Wellington Management Group LLP grew its position in Guardian Pharmacy Services by 3.3% during the 3rd quarter. Wellington Management Group LLP now owns 1,143,729 shares of the company’s stock worth $30,000,000 after purchasing an additional 36,072 shares during the last quarter. Franklin Resources Inc. increased its stake in Guardian Pharmacy Services by 8.2% during the 3rd quarter. Franklin Resources Inc. now owns 1,056,240 shares of the company’s stock valued at $27,705,000 after purchasing an additional 80,033 shares in the last quarter. Vanguard Group Inc. increased its stake in Guardian Pharmacy Services by 9.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,055,102 shares of the company’s stock valued at $27,675,000 after purchasing an additional 88,296 shares in the last quarter. Finally, Boston Partners raised its holdings in shares of Guardian Pharmacy Services by 0.7% in the fourth quarter. Boston Partners now owns 1,054,636 shares of the company’s stock worth $31,995,000 after buying an additional 7,759 shares during the last quarter.

Guardian Pharmacy Services Trading Up 9.8%

Guardian Pharmacy Services stock opened at $43.35 on Friday. Guardian Pharmacy Services has a 12-month low of $19.30 and a 12-month high of $47.02. The firm has a 50-day moving average price of $40.93 and a 200-day moving average price of $37.09. The firm has a market capitalization of $2.16 billion, a PE ratio of 42.09, a price-to-earnings-growth ratio of 2.87 and a beta of 0.10.

Guardian Pharmacy Services (NYSE:GRDNGet Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.26 by $0.03. Guardian Pharmacy Services had a return on equity of 31.45% and a net margin of 4.50%.The company had revenue of $351.77 million for the quarter, compared to the consensus estimate of $340.45 million. As a group, sell-side analysts predict that Guardian Pharmacy Services will post 1.18 earnings per share for the current fiscal year.

Guardian Pharmacy Services Company Profile

(Get Free Report)

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.

See Also

Analyst Recommendations for Guardian Pharmacy Services (NYSE:GRDN)

Receive News & Ratings for Guardian Pharmacy Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardian Pharmacy Services and related companies with MarketBeat.com's FREE daily email newsletter.